Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential

References

• Pusateri AE, McCarthy SJ, Gregory KW et al. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. J. Trauma 54, 177–182 (2003).
   PubMedGoogle Scholar
• Alam HB, Chen Z, Jaskille A et al. Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swine. J. Trauma 56, 974–983 (2004).
   PubMedGoogle Scholar
• Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood coagulation. Science 145, 1310 (1964).
   PubMed Web of Science ®Google Scholar
• •Original description of contact activation and the intrinsic pathway.
   Google Scholar
• MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 2(202), 498–499 (1964).
   Google Scholar
• •Original description and use of the term coagulation cascade.
   Google Scholar
• Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. An empirical study. J. Biol Chem. 269, 23357–23366 (1994).
   PubMed Web of Science ®Google Scholar
• Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. Amathematical simulation. J. Biol. Chem. 269, 23367–23373 (1994).
   PubMedGoogle Scholar
• Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb. Haemost. 85, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• ••New paradigm in coagulation:initiation—amplification—propagation.
   Google Scholar
• Hoffman M. A cell-based model of coagulation and the role of Factor Vila.Blood Rev. 17\(Suppl. 1), S1—S5 (2003).
   PubMedGoogle Scholar
• Kisiel W Davie EW. Isolation and characterization of bovine Factor VII. Biochemistry 14, 4928–4934 (1975).
   PubMed Web of Science ®Google Scholar
• Di Scipio RG, Hermodson MA, Yates SG et al A comparison of human prothrombin, Factor IX (Christmas Factor), Factor X (Stuart Factor), and protein S. Biochemistry 16, 698–706 (1977).
   PubMed Web of Science ®Google Scholar
• Rapaport SI, Rao LVM. The tissue factor pathway: how is has become a 'prima ballerina'. Thromb. Haemost. 74, 7–17 (1995).
   PubMed Web of Science ®Google Scholar
• Radcliffe R, Nemerson Y. Activation and control of Factor VII by activated Factor X and thrombin: isolation and characterization of a single chain form of Factor VII. J. Biol. Chem. 250, 388–395 (1975).
   PubMed Web of Science ®Google Scholar
• Seligsohn U, Osterud B, Brown SF et al. Activation of human Factor VII in plasma and in purified systems: roles of activated Factor IX, kallikrein, and activated Factor XII. J. Clin. Invest. 64, 1056–1065 (1979).
   PubMed Web of Science ®Google Scholar
• Pedersen Ah, Lund-Hansen T, Bisgaard- Frantzen H et al Autoactivation of human recombinat coagultion Factor VII. Biochemistry 28, 9331–9336 (1989).
   PubMedGoogle Scholar
• Nakagaki T, Foster DC, Berkner KL et al. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor-dependent autocativation of human coagulation Factor VII. Biochemistry 30, 10819–10824 (1991).
   PubMedGoogle Scholar
• Wilcox JN, Smith KM, Schwartz SM et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Nati Acad. Sci. USA 86, 2839–2843 (1989).
   PubMed Web of Science ®Google Scholar
• Thim L, Bjoern S, Christensen M et al. Amino acid sequence and post-translational modifications of human Factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry 27,7785–7793 (1988).
   PubMed Web of Science ®Google Scholar
• Banner DW, D'Arcy A, Chene C et al. The crystal structure of the complex of blood coagulation Factor Vila with soluble tissue factor. Nature 380,41–46 (1996).
   PubMed Web of Science ®Google Scholar
• Jurlander B, Thim L, Klausen NK et al. Recombinant activated Factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin. Thromb. Hemost. 27,373–384 (2001).
   PubMed Web of Science ®Google Scholar
• Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus. 19,163–176 (1998).
   Google Scholar
• ••Nice summary of the development ofrecombinant Factor (rF)VIIa up to the point of original US Food and Drug Administration approval.
   Google Scholar
• Macik BG, Lindley CM, Lusher J et al. Safety and initial clinical efficacy of three dose levels of recombinant activated Factor VII (rFVIIa): results of a Phase I study. Blood Coag. Fibrinol 4,521–527 (1993).
   PubMed Web of Science ®Google Scholar
• Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 4, 790–798 (1998).
   PubMed Web of Science ®Google Scholar
• Arkin S, Blei F, Fetten J et al. Human coagulation Factor VIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe hemophilia or with acquired inhibitors. Blood Coag. Fibrinol 11, 255–259 (2000).
   Google Scholar
• Ingerslev J, Thykjaer H, Kudsk-Jensen 0 et al. Home treatment with recombinant activated Factor VII: results from one center. Blood Coag. Fibrinol 9(Suppl. 1), 5107–5110 (1998).
   Google Scholar
• Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor Vila (NovoSeven) in hemophiliacs with inhibitors. Thromb. Haemost 80, 912–918 (1998).
   PubMed Web of Science ®Google Scholar
• Laurian Y, Goudemand J, Negrier C et al. Use of recombinant activated Factor VII as first-line therapy for bleeding episodes in hemophiliacs with Factor VIII or IX inhibitors (NOSEPAC study). Blood Coag. Fibrinol 9, S155—S156 (1998).
   Google Scholar
• Abshire T, Kenet G. Recombinant Factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired Factor VIII or IX inhibitors. J. Thromb. Haemost 2, 899–909 (2004).
   PubMed Web of Science ®Google Scholar
• Erhardtsen E. Ongoing NovoSeven® trials. Intensive Care Med. 28, S248—S255 (2002).
   PubMedGoogle Scholar
• Dejgaard A. Update on Novo Nordisk's clinical trial programme on NovoSeven®. Blood Coag. Fibrinol 14, S39—S41 (2003).
   Google Scholar
• •Concise summary of ongoing clinical trial program.
   Google Scholar
• Hoffman M, Monroe DM. The action of high-dose Vila (FVIIa) in a cell-based model of hemostasis. Dis. Mon. 49,14–21 (2003).
   PubMed Web of Science ®Google Scholar
• ••One view on how rFVIIa works.
   Google Scholar
• Butenas S, Brummel KE, Bouchard BA, Mann KG. How Factor VIIa works in hemophilia. J. Thromb. Haemost 1, 1158–1160 (2003).
   Google Scholar
• ••Alternative view on how rFVIIa works.
   Google Scholar
• van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen Factor VII: implications for the treatment of hemophilia A by Factor Vila. Blood 97,1330–1335 (2000).
   Google Scholar
• ten Cate H, Bauer KA, Levi M et al. The activation of Factor X and prothrombin by recombinant Factor Vila in vivo is mediated by tissue factor. J. Clin. Invest. 92,1207–1212 (1993).
   PubMed Web of Science ®Google Scholar
• Friederich PW, Bauer LM, Bauer KA et al. Ability of recombinant Factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103,2555–2559 (2001).
   PubMed Web of Science ®Google Scholar
• Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant Factor VIIa. Clin. Pharmacol Then 55,638–648 (1994).
   PubMed Web of Science ®Google Scholar
• •One of the classical studies of the pharmacoldnetics of this agent.
   Google Scholar
• Erhardtsen E. Pharmacokinetics of recombinant activated Factor VIIa (rFVIIa). Semin. Thromb. Hemost. 26, 385–391 (2000).
   PubMed Web of Science ®Google Scholar
• Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant Factor VIIa. Blood Coag. Fibrinol 9, 119–128 (1998).
   PubMed Web of Science ®Google Scholar
• ••Good summary of clinical experience with rFVIIa prior to 1998.
   Google Scholar
• Shapiro AD, Gilchrist GS, Hoots KW, Cooper HA, Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. 80,773–778 (1998).
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Freidman D, Gastineau D et al Major surgery in hemophilic patients with inhibitors using recombinant Factor VIIa. Haemostasis 26(Suppl. 1), 118–123 (1996).
   PubMedGoogle Scholar
• Bauer KA. Treatment of Factor VII deficiency with recombinant Factor VIIa. Haemostasis 26(Suppl. 1), 155–158 (1996).
   PubMedGoogle Scholar
• Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant Factor VII in the treatment of congenital Factor VII deficiencies. Vox Sanguinis77, 131–136 (1999).
   Google Scholar
• Jimenez-Yuste V, Villar A, Morado M et al Continuous infusion of recombinant activated Factor VII during cesarean section delivery in a patient with congenital Factor VII deficiency. Haemophilia 6, 588–590 (2000).
   PubMedGoogle Scholar
• Poon MC, D'Oiron R, and the International Registry on Recombinant Factor Vila and Congenital Platelet Disorders Group. Recombinant activated Factor VII (NovoSeven®) treatment of platelet-related bleeding disorders. Blood Coag. Fibrinol 11\(Suppl. 1), S55—S68 (2000).
   PubMedGoogle Scholar
• Almeida AM, Khair K, Hann I, Liesner R The use of recombinant Factor Vila in children with inherited platelet function disorders. Br. J. Haematol 121,477–481 (2003).
   PubMed Web of Science ®Google Scholar
• Al Douri M, Shafi T, Al Khuadairi D et al. Effect of the administration of recombinant activated Factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coag. Fibrinol 1 l\(Suppl. 1),5121—S127 (2000).
   Google Scholar
• Friederich PW, Henny CP, Messelink EJ et al Effect of recombinant activated Factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind, placebo-controlled, randomised trial. Lancet 361, 201–205 (2003).
   PubMed Web of Science ®Google Scholar
• Meijer K, Peters FTM, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant Factor VIIa. Blood Coag. Fibrinol 12,211–213(2001).
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Aberle R. Recombinant Factor Vila (NovoSeven®) for post-prostatectomy hemorrhage in a patient with Type I von Willebrand disease. Am. J. Hematol. 68,62–62 (2001).
   PubMedGoogle Scholar
• Majumdar G, Phillips JK, Lavallee H, Savidge GE Acquired hemophilia in association with Type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant Factor Vila. Blood Coag. Fibrinol. 4,1035–1037 (1993).
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated Factor VII independent of tissue factor. Blood Coag Fibrinol. 9\(Suppl. 1), S15—S20 (1998).
   Google Scholar
• Lauri= Y. Treatment of bleeding inm patients with platelet disorders: is there a place for recombinant Factor Vila? Pathophysia Haemost. Thromb. 32(Suppl. 1), 37–40 (2002).
   Google Scholar
• d'Oiron R, Menart C, Trzeciak MC et al. Use of recombinant Factor Vila in three patients with inherited Type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb. Haemost. 83,644–647 (2000).
   PubMedGoogle Scholar
• Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant Factor Vila. Bone Marrow Transplant. 30,975–978 (2002).
   PubMed Web of Science ®Google Scholar
• Meijer K, deGraaffW, Daenen SM. Successful treatment of massive hemoptysis in acute leukemia with recombinant Factor Vila. Arch. Intern. Med. 160, 2216–2217 (2000).
   PubMedGoogle Scholar
• Blatt J, Gold SH, Wiley JM. Off-label use of recombinant Factor Vila in patients following bone marrow transplantation. Bone Marrow Transplant. 28,405–407 (2001).
   PubMed Web of Science ®Google Scholar
• Kamphuisen PW, Van den Akker JM, Kaasjager KAH. Control of life-threatening pulmonary bleeding with activated recombinant Factor VII. Am. J. Med. 112, 332–333 (2002).
   PubMedGoogle Scholar
• Escobar MA. Reversal of coumarin-induced over-anticoagulation (5) (multiple letters). Br. J. Haematol. 118,925–926 (2002).
   PubMedGoogle Scholar
• Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human Factor Vila concentrate. Ann. Intern. Med 137, 884–888 (2002).
   PubMed Web of Science ®Google Scholar
• •rFVlIa rapidly and efficiently corrects the international normalized ratio for prothrombin activity in excessive oral anticoagulation, but is a very expensive way to achieve this result.
   Google Scholar
• Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant Factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106, 2550–2554 (2002).
   PubMed Web of Science ®Google Scholar
• Bijsterveld NR, Vink R, van Aken BE et al. Recombinant Factor Vila reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br. J. Haemotol. 124,653–658 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein D. Effectiveness of the recombinant Factor Vila in patients with the coagulopathy of advanced child's B and C cirrhosis. Semin. Thromb. Hemost. 26,437–438 (2000).
   PubMed Web of Science ®Google Scholar
• Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinat Factor Vila in patients with liver disease undergoing laparoxcopic liver biopsy. Gastroenterology 123,118–126 (2002).
   PubMed Web of Science ®Google Scholar
• Young G, Nugent DJ. Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant Factor Vila. Hematology 6, 341–346 (2001).
   PubMedGoogle Scholar
• Kositchaiwat C, Chuansumrit A. Experiences with recombinant Factor Vila for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (FRCP). Thromb. Haemost. 86,1125–1126 (2001).
   PubMed Web of Science ®Google Scholar
• Hendriks HG, Meijer K, de Wolf JTM et al. Reduced transfusion requirements by recombinant Factor Vila in orthotopic liver transplantation. Transplantation 71 402–405 (2001).
   Google Scholar
• Hendriks HG, Meijer K, de Wolf JTM et al. Effects of recombinant activated Factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coag. Fibrinol. 13, 309–313 (2002).
   PubMed Web of Science ®Google Scholar
• Meijer K, Hendriks HG, De Wolf JT et al. Recombinant Factor Vila in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coag. Fibrinol. 14,169–174 (2003).
   PubMedGoogle Scholar
• Lodge JP. Hemostasis in liver resection surgery. Semin. Hematol. 41(Suppl. 1), 70–75 (2004).
   PubMedGoogle Scholar
• Arkin S, Cooper HA, Hutter JJ. Activated recombinant human coagulation Factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Haemostatsis 28, 93–98 (1998).
   PubMedGoogle Scholar
• Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial hemorrhage in severe neonatal FVII deficiency. Haemophilia 6,50–54 (2000).
   PubMedGoogle Scholar
• Pickard JD, Kirkpatrick PJ, Melsen T et al. Potential role of NovoSeven® in the prevention of rebleeding following aneurismal subarachnoid hemorrhage. Blood Coag. Fibrinol. 11\(Suppl. 1), S117—S120 (2000).
   PubMedGoogle Scholar
• Gerlach R, Marquardt G, Wissing H et al. Application of recombinant activated Factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostatsis. J. Neurosurg. 96, 946–947 (2002).
   PubMedGoogle Scholar
• Billon S, Le Niger M, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant Factor Vila (NovoSeven®) in a patient with Factor XI deficiency and a circulating anticoagulant. Blood Coag. Fibrinol. 12,551–553 (2001).
   PubMed Web of Science ®Google Scholar
• Lawler P, White B, Pye S et al. Successful use of recombinant Factor Vila in a patient with inhibitor secondary to severe Factor XI deficiency. Haemophilia 8, 145–148 (2002).
   PubMed Web of Science ®Google Scholar
• Marsh JCW, Bevan DH. Hematological care of the Jehovah's Witness patient. Br. J. Haematol. 119,25–37 (2002).
   PubMed Web of Science ®Google Scholar
• Waddington DP, McAuley FT, Hanley JP et al. The use of recombinant Factor Vila in a Jehovah's Witness with autoimmune thrombocytopenia and postsplenectomy hemorrhage. Br. J. Haematol. 119,286 (2002).
   PubMedGoogle Scholar
• Tanaka KA, Waly AA, Cooper WA et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant Factor Vila (NovoSeven). Anesthesiology 98, 1513–1515 (2003).
   PubMed Web of Science ®Google Scholar
• Lusher JM. Inhibitor antibodies to Factor VIII and Factor IX: management. Semin. Thromb. Hemost. 26,179–188 (2000).
   PubMed Web of Science ®Google Scholar
• Negrier C, Hay CRI\4. The treatment of bleeding in hemophilic patients with inhibitors with recombinant Factor Vila. Semin. Thromb. Haemost. 26,407–412 (2000).
   PubMedGoogle Scholar
• Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringer A. Relationship between Factor VII activity and clinical efficacy of recombinant Factor Vila given by continuous infusion to patients with Factor VIII inhibitors. Thromb. Haemost. 86,954–958 (2001).
   PubMed Web of Science ®Google Scholar
• Von Depka M. NovoSeveng: mode of action and use in acquired hemophilia. Intensive Care Med. 28, S222—S227 (2002).
   PubMed Web of Science ®Google Scholar
• Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant Factor VIIa. Semin. Hematol 41(Suppl. 1), 20–24 (2004).
   PubMedGoogle Scholar
• Carr ME, Martin EJ. Laboratory assessment of hemostatic function in whole blood samples. Clin. Lab. (2004) (In press).
   Google Scholar
• Carr ME, Martin EJ, Ambrose H. Fibrin Sealants. Encyclopedia of Biomaterials and Biomedical Engineering. Wnek G, Bowlin GL (Eds), Marcel Dekker, Inc., NY, USA (2004).
   Google Scholar
• ••Brief review of potential and evolvingassays for monitoring rFVlIa.
   Google Scholar
• Sakai T, Lund-Hansen T, Thim L, Kisiel W. The y-carboxyglutamic acid domain of human factor Mina is essential for its interaction with cell surface tissue factor. J. Biol. Chem. 265,1890–1894 (1990).
   PubMed Web of Science ®Google Scholar